Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,446 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard response Clear all
Recruiting Phase 2 Interventional

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

NCT07313241
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Fossa Radiotherapy, Pelvic nodal Radiotherapy, Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Terminated No phase listed Observational

A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer

NCT04655573
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Breast Cancer Tumor Resection
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 25, 2026, 9:00 PM EDT
Terminated Not applicable Interventional

Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2

NCT02218151
View directory record Official record
Conditions
Blood Disorders
Interventions
Patient-Centered Medical Home (PCMH), Standard Care
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

NCT00201123
View directory record Official record
Conditions
Tuberculosis, AIDS-related Complex
Interventions
Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Not applicable Interventional Results available

Deployment of American Heart Association Heart Failure Protocols and Content Within the Intel® Health Guide System

NCT01275846
View directory record Official record
Conditions
Heart Failure
Interventions
Health Guide using AHA heart failure protocols and content
Device
Lead sponsor
American Heart Association
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Warrensville Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 25, 2026, 9:00 PM EDT
Recruiting Not applicable Interventional

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

NCT07704918
View directory record Official record
Conditions
Melanoma
Interventions
Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

NCT00335816
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy, laboratory biomarker analysis, DNA analysis, polymerase chain reaction, immunohistochemistry staining method
Drug · Procedure · Radiation + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
14
States / cities
Concord, California • Duarte, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Active, not recruiting Phase 1 Interventional

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

NCT05934838
View directory record Official record
Conditions
Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma
Interventions
Tazemetostat Pill
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Phase 1Phase 2 Interventional

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

NCT04431258
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ABTL0812, Folfirinox, Placebo
Drug
Lead sponsor
Ability Pharmaceuticals SL
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Phase 2 Interventional

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

NCT04401774
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma (PCNSL)
Interventions
Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Phase 3 Interventional

Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass

NCT00587444
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Heparin, HH or high heparin, heparin concentration HC
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Not applicable Interventional Results available

Tailored Drug Titration Using Artificial Intelligence

NCT04223934
View directory record Official record
Conditions
Hypertension
Interventions
optima4BP
Other
Lead sponsor
Optima Integrated Health
Industry
Eligibility
21 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Metabolic Response of Unweighted Treadmill Walking

NCT07870434
View directory record Official record
Conditions
Metabolic Testing
Interventions
AlterG Treadmill, Metabolic Assessment
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 30 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
East Meadow, New York • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Phase 2 Interventional

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

NCT03616834
View directory record Official record
Conditions
Solid Tumors
Interventions
Tomivosertib (eFT-508)
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Not applicable Interventional

Effects of Animal Assisted Activity on Biobehavioral Stress Responses of Hospitalized Children: A Randomized Control Trial

NCT03017027
View directory record Official record
Conditions
Psychosocial Stress
Interventions
Therapy dog visitation (TDV), non-TDV control
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 25, 2026, 9:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Recruiting Not applicable Interventional

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

NCT06055894
View directory record Official record
Conditions
Multiple Myeloma, Smoldering, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Omega-3, Curcumin, Probiotic, Whole food, plant-based diet (WFPBD)
Dietary Supplement · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Luspatercept + Darbepoetin in MDS

NCT07096297
View directory record Official record
Conditions
MDS (Myelodysplastic Syndrome)
Interventions
Luspatercept, Darbeopoetin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
4
States / cities
New Haven, Connecticut • Chicago, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Completed No phase listed Observational Results available

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

NCT02218320
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Raltegravir, Dolutegravir, Colonoscopy with biopsy
Drug · Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 25, 2026, 9:00 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

NCT06216249
View directory record Official record
Conditions
Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors

NCT05660408
View directory record Official record
Conditions
Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma
Interventions
pp65 RNA LP (DP1), pp65/tumor mRNA RNA-LP (DP2), Surgical Biopsy/Resection
Biological · Procedure
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 39 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Not applicable Interventional Results available

Intelligent Control Approach to Anemia Management

NCT00572533
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
ESA Dose Adjustment per standard Anemia Management Protocol, ESA Dose Adjustment per "Smart Anemia Manager" Algorithm
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 25, 2026, 9:00 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma

NCT04831138
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
MRI with ASL, ASL-MRI
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 25, 2026, 9:00 PM EDT
Completed Phase 1Phase 2 Interventional

My Scrivener® - Measuring Effectiveness and Dose Response in Children

NCT00919906
View directory record Official record
Conditions
Asperger's Syndrome, Dyslexia, Cerebral Palsy, Attention Deficit Disorder, ADHD, Traumatic Brain Injury, Stroke
Interventions
My Scrivener(R)
Device
Lead sponsor
Obslap Research LLC
Industry
Eligibility
5 Years to 19 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2010 · Synced Oct 25, 2026, 9:00 PM EDT